Avaleht › Ajuvähid › Massachusetts › Boston
Ajuvähid kliinilised uuringud linnas Boston, MA
28 uuringut haiguse Ajuvähid jaoks otsivad osalejaid linnas Boston ja selle ümbruses (umbes 30 miili raadiuses). Avage uuring, et näha, kes saab osaleda ja kuidas võtta ühendust uuringumeeskonnaga.
Ametlik uuringutekst (inglise keeles)
Otsite osalejaid uuringusse? Esitlege seda selle lehe tipus – $99 30 päeva eest →
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
VärbamineFaas 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
VärbamineFaas 1/2
- Tufts Medical Center, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
VärbamineFaas 1/2
- Dana-Farber Cancer Institute, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
VärbamineFaas 2
- Local Institution - 0124, Boston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
VärbamineFaas 1
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
Värbamine
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
VärbamineFaas 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
VärbamineFaas 1/2
- Dana-Farber Cancer Institute, Boston
Targeted Pediatric High-Grade Glioma Therapy
VärbamineVaatlusuuring
- Dana-Farber Cancer Institute, Boston
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
VärbamineFaas 2
- Massachusetts General Hospital, Boston
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
VärbamineFaas 2
- Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
VärbamineFaas 2
- Brigham and Women's Hospital, Boston
B7-H3.CD28Z.CART in CNS Neoplasms
VärbamineFaas 1
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
VärbamineFaas 2
- Susan Chi, Boston
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
Värbamine
- Massachusetts General Hospital, Boston
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
VärbamineVaatlusuuring
- Beth Israel Deaconess Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
Palbociclib and Pembrolizumab In Central Nervous System Metastases
VärbamineFaas 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
VärbamineFaas 3
- Tufts Medical Center, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
VärbamineFaas 2
- Dana-Farber Cancer Institute, Boston
NTS-WBRT in Brain Metastases
VärbamineFaas 2
- Massachusetts General Hospital Cancer Center, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
VärbamineFaas 1/2
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
Värbamine
- Massachusetts General Hospital Cancer Center, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
Värbamine
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
VärbamineVarajane 1. faas
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital Cancer Center, Boston
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
VärbamineFaas 1/2
- Beth Israel Deaconess Medical Center, Boston
ASCENT Intervention for Brain Tumor Patients
Värbamine
- Massachusetts General Hospital Cancer Center, Boston
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
VärbamineVaatlusuuring
- Massachusetts General Hospital, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
VärbamineVaatlusuuring
- Massachusetts General Hospital, Boston
Ajuvähid uuringud teistes linnades
- Houston, TX35 uuringut
- New York City, NY25 uuringut
- Washington, DC20 uuringut
- Los Angeles, CA16 uuringut
- Miami, FL15 uuringut
- Durham, NC14 uuringut
- St. Louis, MO12 uuringut
- Cleveland, OH11 uuringut
- Seattle, WA11 uuringut
- Rochester, MN11 uuringut
- Baltimore, MD11 uuringut
- Columbus, OH11 uuringut
Muud uuringud linnas Boston
- Rinnavähk111 uuringut
- Mitteväikerakuline kopsuvähk90 uuringut
- Vähk (kõik liigid)86 uuringut
- Käär- ja pärasoolevähk63 uuringut
- Metastaatiline vähk63 uuringut
- Kopsuvähk62 uuringut
- Munasarjavähk61 uuringut
- Eesnäärmevähk59 uuringut
- Depressioon52 uuringut
- Endomeetriumivähk50 uuringut
- Südamepuudulikkus44 uuringut
- Äge müeloidne leukeemia44 uuringut
Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.